FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

Calliditas Therapeutics AB, announced that the U.S. Food and Drug Administration has accepted the submission for the supplemental New Drug Application for TARPEYO® delayed release capsules and granted Priority Review.

Scroll to Top